Accueil / Nouvelles et Évènements
Communiqué de presse
GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund
Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
GlycoNet researchers develop new chemical biological tools to monitor Parkinson’s disease
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
More stories
- Tout
- Prix
- Communauté
- Profil du Réseau
- Communiqué de presse
- Points saillants de la recherche
Engagement and collaboration in action at the 2022 Canadian Glycomics Symposium
Read some highlights from the 2022 Canadian Glycomics Symposium.
Enzymes linked with immune cell activity could hold key to better understanding inflammation
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
GlycoNet researcher receives Scientific Achievement and Innovation Award
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
New research reveals clues to how antibodies get fine-tuned to fight infection
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
Réseau Canadien de la Glycomique
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tél.: 780-492-6204
Téléc.: 780-492-4147
Subscribe to GlycoNet’s Newsletter
© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.
French 
English